Skopos Labs, Inc. Catalyst Pharmaceuticals, Inc. Transaction History
Skopos Labs, Inc.
- $497 Million
- Q2 2025
A detailed history of Skopos Labs, Inc. transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Skopos Labs, Inc. holds 752 shares of CPRX stock, worth $15,769. This represents 0.0% of its overall portfolio holdings.
Number of Shares
752
Previous 752
-0.0%
Holding current value
$15,769
Previous $18,000
11.11%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding CPRX
# of Institutions
385Shares Held
103MCall Options Held
0Put Options Held
277K-
Black Rock Inc. New York, NY18.7MShares$392 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.77MShares$184 Million0.0% of portfolio
-
State Street Corp Boston, MA5.48MShares$115 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny3.25MShares$68.2 Million0.1% of portfolio
-
Morgan Stanley New York, NY3.18MShares$66.8 Million0.0% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.16B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...